Not medical advice. Talk to your provider before using any peptide. Full disclaimer
Argireline
Also known as: Acetyl Hexapeptide-3, Acetyl Hexapeptide-8, AH-8
One clinical trial measured 48.9% wrinkle reduction in four weeks. Another found zero statistically significant change. That split tells you everything about Argireline (Acetyl Hexapeptide-8, CAS 616204-22-9), a six-amino-acid topical peptide that competes with SNAP-25 to slow acetylcholine release at the neuromuscular junction. The mechanism mirrors botulinum toxin, but less than 0.01% of the applied peptide actually reaches the epidermis. Skincare enthusiasts use it twice daily at 10% concentration to soften forehead lines and crow's feet. It works for some people. For others, the serum vehicle does all the heavy lifting.
What Is Argireline?
Argireline (Acetyl Hexapeptide-8, formerly Acetyl Hexapeptide-3, CAS 616204-22-9) is a synthetic hexapeptide with the sequence Ac-EEMQRR-NH2 and a molecular weight of 889 Da. Clinical results are polarizing: 48.9% composite wrinkle reduction in one trial, zero significant effect in another, both using the same concentration. Developed by Lipotec (now Lubrizol), it was designed to mimic residues 12 through 17 of the SNAP-25 N-terminal domain. That stretch of amino acids participates in assembling the SNARE complex, the molecular machinery behind acetylcholine release at neuromuscular junctions.
By competing with SNAP-25 for its binding position, Argireline reduces the efficiency of vesicle fusion. Muscle contractions weaken. Dynamic wrinkles soften. Unlike botulinum toxin type A, which proteolytically cleaves SNAP-25, the inhibition is reversible and dose-dependent.
The catch is penetration. In vitro data from Kraeling and colleagues [1] shows 0.22% retention in the stratum corneum. Roughly 0.01% reaches the epidermis. Nothing detectable arrives in the dermis. The neuromuscular mechanism that makes Argireline interesting on paper may not operate at topical doses.
Clinical evidence is mixed. Wang and colleagues [2] ran a placebo-controlled trial with 60 subjects and reported statistically significant roughness reduction (p < 0.01) at four weeks. A 2023 double-blind split-face study with 19 subjects (PMC10665711) found no significant between-group difference. Community evidence is large; one popular over-the-counter 10% serum has 200,000 plus reviews (3.9 out of 5 stars). Responders are vocal. Non-responders are equally vocal.
Argireline is classified as a cosmeceutical ingredient. It has no FDA approval for any medical indication. The CIR Expert Panel confirmed its safety in cosmetic formulations.
How Argireline Works
The SNARE complex is a three-protein machine. Syntaxin-1 and SNAP-25 sit on the presynaptic membrane. VAMP (synaptobrevin-2) anchors to the synaptic vesicle. When these three proteins zip together, they generate enough force to fuse the vesicle with the membrane and dump acetylcholine into the synaptic cleft. That acetylcholine triggers muscle contraction.
Argireline's six-amino-acid sequence (Ac-EEMQRR-NH2) copies residues 12 through 17 of SNAP-25's N-terminal SNARE motif. The peptide inserts itself into the binary interaction between SNAP-25 and syntaxin, the first step of SNARE assembly. With Argireline occupying that binding site, the ternary complex can't form efficiently.
Less complex formation means fewer vesicles fuse. Fewer fused vesicles means less acetylcholine in the cleft. Less acetylcholine means weaker contraction of the frontalis, orbicularis oculi, and corrugator supercilii muscles. Those are the muscles that carve forehead furrows, crow's feet, and glabellar frown lines over years of repeated expression.
The pharmacological distinction from botulinum toxin is important. Botulinum toxin type A irreversibly cleaves SNAP-25 through proteolysis. The nerve terminal has to grow new SNAP-25 before function returns. Argireline is a competitive inhibitor; it modulates contraction rather than eliminating it. Stop applying it, and normal SNARE assembly resumes within weeks.
One unresolved question hangs over the entire mechanism. In vitro penetration studies show less than 0.01% of applied Argireline reaching the epidermis. Whether enough peptide reaches neuromuscular junctions to produce the measured wrinkle reduction (or whether the effect is partly vehicle-driven) is something the published literature has not settled.
Argireline Benefits
- Argireline benefits center on softening dynamic expression wrinkles through a topical, non-invasive approach.
- Up to 48.9% composite anti-wrinkle efficacy at four weeks in a 60-subject placebo-controlled trial (Wang et al. 2013)[2], with statistically significant roughness reduction across all measured parameters (p < 0.01).
- Blanes-Mira and colleagues [3] measured 30% wrinkle depth reduction by day 30 using a 10% formulation, making it one of the faster-acting topical peptides on the market.
- No needles, no downtime, no prescription needed. Over-the-counter 10% serums start around $10 per 30ml, making this one of the most accessible peptide protocols available.
- Fully reversible mechanism; facial expression stays natural because SNARE inhibition modulates contraction rather than paralyzing it.
- Compatible with SNAP-8, Matrixyl, GHK-Cu, and hyaluronic acid in layered routines, which is why it appears in most serious multi-peptide anti-aging stacks.
- Some users report extending the interval between botulinum toxin appointments by applying Argireline between sessions, though no controlled trial has confirmed this specific use case.
Argireline: Science vs Community Consensus
Modest, inconsistent efficacy for expression line reduction at 10% concentration.
Read the evidence (key study, limitations)
Two positive RCTs (n=60 and open-label n=10) support benefit; one 2023 double-blind n=19 RCT found no statistically significant effect. Primary limitation is penetration: <0.01% of applied peptide reaches the epidermis, raising mechanistic questions about neuromuscular access.
Wang et al. 2013 (PMID 23417317): RCT n=60, 48.9% composite anti-wrinkle efficacy at 4 weeks (p<0.01); counterbalanced by PMC10665711 (2023) n=19 double-blind split-face: p=0.060 treated side, p=0.829 between-group: no significant effect.
Small sample sizes; industry-adjacent funding in positive trials; no confirmed neuromuscular mechanism in vivo at topical doses; penetration barrier (<0.01% epidermis); no placebo-matched studies exceeding 60 subjects.
Broadly popular for softening forehead furrows and crow's feet.
Read the reports (what users report 4, common issues 4)
Results are polarized: enthusiastic responders report visible improvement; a meaningful minority sees no effect. The "Botox in a bottle" label drives adoption but also disappointment when results don't match Botox.
- Visible softening of forehead furrows and crow's feet with consistent 10% twice-daily use over 4 weeks
- Non-invasive, no downtime, no needles: accessible to mass market at $10/30ml
- Compatible with HA, niacinamide, vitamin C, and other peptides (SNAP-8, Matrixyl, GHK-Cu)
- Bridges time between Botox appointments for some users
- High non-responder rate: consistent with null 2023 RCT; many users report no visible change
- Anecdotal "sagging effect" or "heaviness" around eyes with overuse: not documented in any trial but recurs across Reddit threads
- "Botox in a bottle" marketing creates unrealistic expectations; penetration data contradicts the neuromuscular mechanism at topical doses
- Results are not permanent: return to baseline within 4–8 weeks of stopping
Both science and community accept Argireline can reduce surface wrinkle appearance, but the community believes more strongly than the evidence supports. Science is split on whether the effect is real vs. vehicle-driven. The penetration data creates a mechanistic gap that neither fully resolves.
Argireline Dosage Guide
| Level | Dose | Frequency |
|---|---|---|
| Beginner | 2 mg | 2x Daily |
| Moderate | 5 mg | 2x Daily |
| Aggressive | 10 mg | 2x Daily |
Start with a 5% concentration for the first two weeks if your skin runs reactive. One study landed on nearly identical wrinkle reduction at 5% vs. 10% (16.26% vs. 17%), so you're not losing much during the tolerance phase. After that, step up to 10% twice daily.
Argireline is a topical peptide, not an injectable. There's no vial to reconstitute, no bacteriostatic water, no syringe math. It comes as a ready-to-use serum or cream. A plain 10% over-the-counter serum is the community benchmark for setting expectations.
The thing most beginners miss: check the label carefully. Some products list "contains Argireline" when the peptide is a trace ingredient in a blend. You want 10% Acetyl Hexapeptide-8 as the active, listed early in the INCI order.
Apply to clean, dry skin before moisturizer. Morning and evening. Give it 2 to 3 minutes to absorb before layering. Refrigerate opened bottles and use within six months.
Cycling Protocol
Apply twice daily for 12 weeks to allow cumulative wrinkle reduction. Clinical improvement typically begins around week 2-3 and peaks at week 4-8. A 2-week break is optional: no receptor desensitization or tachyphylaxis has been reported, so continuous long-term use is commonly practiced. Effects are reversible and diminish gradually over 4-8 weeks after discontinuation as normal SNARE complex function resumes.
Argireline has no documented receptor desensitization, tachyphylaxis, hormonal axis effects, or antibody formation. Cycling is not pharmacologically required. The standard 12-week-on / 2-week-off practice listed for it is derived from cosmetic study durations (most trials lasted 4–12 weeks) and provides a natural reassessment window rather than a biological necessity. Continuous long-term use is widely practiced and no adverse effects from sustained use have been documented in the CIR safety assessment or clinical literature.
- No signs indicating mandatory cycling: discontinuation and restart are user preference
- Gradual return of expression lines within 4–8 weeks of stopping confirms reversibility and provides a natural "off" comparison
Or use the universal Peptide Calculator for any peptide.
Argireline Protocols by Goal
Expected: Modest softening of fine expression lines by week 4; non-responders apparent by week 8
Monitor: Self-assessment of expression line depth at 4 and 8 weeks. Discontinue if contact dermatitis develops.
How to Use Argireline
- 1Cleanse your face and pat dry completely
Argireline absorbs best on clean, dry skin without competing products underneath.
- 2Step 2
Dispense 3 to 4 drops of 10% Argireline serum onto your fingertips.
- 3Step 3
Apply a thin layer to target expression-line areas: forehead horizontals, crow's feet, glabellar frown lines, and periorbital region. Use gentle tapping motions rather than rubbing.
- 4Step 4
Wait 2 to 3 minutes for absorption before applying your next product.
- 5Layer moisturizer on top
In the morning, follow with sunscreen (SPF 30 or higher).
- 6Step 6
Repeat morning and evening for at least four weeks before evaluating results.
- 7
- 8Step 8
Timing with retinol: apply Argireline in the morning, retinol in the evening. Don't layer them simultaneously.
- 9Step 9
After chemical exfoliation at peel-strength concentrations (glycolic above 20%), wait 48 to 72 hours before resuming Argireline.
- 10Step 10
Do not apply to broken, inflamed, or sunburned skin.
- 11Step 11
Store opened serum at 2 to 8 degrees Celsius away from direct light. Room temperature is acceptable for sealed commercial products with preservative systems.
Note: Argireline is a topical peptide, not an injectable. There are no syringe unit calculations for this product. The dosing tiers (2 mg beginner, 5 mg moderate, 10 mg aggressive twice daily) reflect approximate milligrams of active peptide per application when using commercial serums at standard concentrations.
Alternative Routes
N/A: this is the reference route
All published RCTs used topical emulsion or serum. In vitro penetration: 0.22% retained in stratum corneum, <0.01% reaches epidermis, nothing detectable in dermis (PMID 24754410).
Same 5–10% active concentration but potentially higher dermal bioavailability due to lipid carrier bypassing the hydrophilic barrier limitation
Multiple-water-in-oil-in-water (w/o/w) emulsions and phosphatidylcholine liposomes show improved AH-8 retention in deeper skin layers in ex vivo models (referenced in PMC12193160). No commercial benchmark at this formulation type yet. DIY liposomal encapsulation is technically complex.
Lower % concentration may be required as delivery efficiency is dramatically higher; exact equivalent dose not established
Dissolving microneedle patches with AH-8 have been studied in vitro showing meaningful dermal deposition. No commercial microneedle patch product for Argireline is widely available as of 2026. Most accessible approach is using a 0.25–0.5mm dermaroller prior to standard topical application (community practice; no RCT data).
Argireline Stacking Protocols
Works With
Same SNARE complex inhibition mechanism, longer octapeptide sequence. Additive neuromuscular effect at the same target site. Frequently combined in multi-peptide anti-wrinkle serums.
Argireline 10% AM + SNAP-8 10% PM; or combined in same serum formulation
Collagen-stimulating mechanism (TGF-β pathway) complements surface wrinkle relaxation. Addresses structural collagen loss while Argireline targets neuromuscular dynamic wrinkles.
Combined in same serum or layered AM routine; both 2x daily
Collagen/elastin remodeling and wound-healing support at a different mechanistic layer. GHK-Cu works deeper on ECM structure; Argireline on surface neuromuscular relaxation. Frequently combined in anti-aging protocols.
Argireline AM; GHK-Cu PM or combined in the same multi-peptide serum
Waglerin-1-mimetic peptide that blocks postsynaptic nicotinic acetylcholine receptors: a third, complementary neuromuscular relaxation pathway distinct from Argireline's presynaptic SNARE inhibition.
Combined in premium multi-peptide serums; each at 4–8% concentration
Avoid
Compromised barrier post-peel alters peptide absorption unpredictably. May cause excessive irritation or sensitization.
Do not apply topicals to injection sites immediately after Botox. Theoretical additive muscle relaxation effect in the treatment zone; skin trauma from injection alters topical absorption.
Estimated Cost
Pricing updated 2026-04-09
Argireline Side Effects
The biggest concern with Argireline is not a side effect. It's the anecdotal reports of periorbital heaviness and a "sagging" sensation around the eyes with heavy use. No published trial has documented this, but it recurs across Reddit threads with enough consistency to warrant attention. If you notice your eyelids feeling heavier after several weeks of use, reduce application frequency around the eyes to once daily (evening only) or stop using it in the periorbital area altogether.
From a clinical standpoint, the side effect profile is genuinely mild. Published studies report no significant adverse events compared to vehicle control. Kraeling and colleagues [1] showed less than 0.3% of applied peptide penetrates beyond the skin surface, so systemic effects are not a realistic concern.
Skin irritation at the application site can occur. Mild redness or a tingling sensation after application is the most commonly reported reaction, particularly in people with reactive or sensitized skin. In the blepharospasm pilot study [4], minor eyelid irritation was attributed to the cream vehicle rather than Acetyl Hexapeptide-8 itself.
Allergic contact dermatitis is possible but rare. If you develop persistent redness or itching, stop for one week. If symptoms resolve, reintroduce every other day. If they persist, patch-test the individual ingredients because the reaction may be to phenoxyethanol or propanediol in the serum base.
No oral toxicity or primary irritation was observed at high doses in preclinical safety testing. The CIR Expert Panel reviewed the safety data and confirmed the ingredient is safe for cosmetic use.
A few practical cautions apply. Don't apply Argireline immediately after a strong chemical peel (glycolic acid above 20%, TCA peels); a compromised barrier changes absorption unpredictably. Wait 48 to 72 hours post-peel before resuming. If you're also receiving botulinum toxin injections, avoid applying topicals to the injection sites for at least 24 to 48 hours.
Pregnancy and breastfeeding: no safety data exists for these populations. Standard practice is to avoid use. The same applies to children under 18.
Common Issues & Solutions
No visible result after 8 weeks: Likely a non-responder or using a low-quality formulation. Verify product is 10% concentration and not a "blend" where Argireline is a minor ingredient. Testing a plain 10% serum first rules out a weak formulation before concluding non-response.
Periorbital heaviness or "sagging" sensation around eyes: Recurs in anecdotal reports; not documented in trials. Reduce application frequency in periorbital region to once daily (PM only) or discontinue use there. Do not increase concentration.
Contact dermatitis or persistent redness at application site: Discontinue for 1 week. If resolved, reintroduce every other day. If persists, patch-test individual components: reaction may be to the serum vehicle (phenoxyethanol, propanediol) rather than the peptide itself.
Irritation when layering with vitamin C or retinol: Apply Argireline and vitamin C in separate steps with absorption time in between, or use vitamin C AM and Argireline PM. Never apply Argireline immediately after a strong acid exfoliant: wait 24–48 hours minimum.
Results disappeared after stopping: Expected. Effects are not permanent: SNARE complex inhibition is reversible. Resume 2x daily protocol; improvement typically returns within 1–2 weeks of consistent use.
Ask AI about this page
Ask AI for a second opinion on Argireline dosing and side effects
Contraindications
- Known allergy or hypersensitivity to acetyl hexapeptide-8 or any component amino acid (glutamic acid, methionine, glutamine, arginine)
- Active skin infections, open wounds, or severe dermatitis at intended application sites
- Pregnancy or breastfeeding (no safety data available for these populations)
- Children under 18 (insufficient safety data)
- History of contact dermatitis to cosmeceutical peptide products
- Concurrent use at injection sites immediately following botulinum toxin treatment (allow 24-48 hours post-injection before applying topicals to treated areas)
Drug Interactions
- Botulinum toxin (Botox, Dysport, Xeomin): both target the SNARE complex; combined use may theoretically increase muscle relaxation effects. Some practitioners use Argireline between Botox appointments to extend results, but consult a dermatologist
- Other SNARE-modulating topical peptides (SNAP-8, Leuphasyl/Pentapeptide-18): additive neuromuscular effects are expected and have been studied in combination protocols; monitor for excessive facial muscle relaxation
- Topical retinoids (tretinoin, adapalene): may increase skin sensitivity when layered simultaneously; apply at separate times of day for best tolerance
- High-concentration chemical peels (glycolic acid >20%, TCA peels): compromised skin barrier after peeling may alter peptide absorption; wait 48-72 hours post-peel before resuming
- Topical corticosteroids: prolonged steroid use thins the epidermis and may alter peptide retention and penetration characteristics
- Do not apply topicals to injection sites immediately after Botox. Theoretical additive muscle relaxation effect in the treatment zone; skin trauma from injection alters topical absorption.
Product Quality
Sold as a standard OTC cosmeceutical ingredient regulated under cosmetics law (FDA 21 CFR, EU Cosmetics Regulation). Over-the-counter serums from established brands undergo standard cosmetic GMP manufacturing and preservative efficacy testing. The raw ingredient (AH-8) is a well-characterized synthetic hexapeptide made by Lipotec/Lubrizol. Primary quality variable for consumers is actual % concentration: some products list Argireline as a minor ingredient in a "peptide blend" rather than at the labeled 10%.
- Choose products that explicitly state "Argireline 10%" or "Acetyl Hexapeptide-8 10%" on the label; "contains Argireline" as a minor ingredient is not enough
- A plain 10% argireline solution is a useful reference point; compare other products by their stated argireline concentration
- Raw AH-8 powder for DIY formulation: a valid CoA shows purity ≥98%
- Refrigerate opened serums; avoid sunlight exposure which may degrade the peptide; use within 6 months of opening
- Check ingredient list placement: Argireline should appear relatively early in the INCI list if truly at 10% concentration
Recommended Monitoring
| Test | When | Target |
|---|---|---|
| Baseline + 4-week photography (expression lines) | Week 0 and Week 4 | Visible reduction in expression line depth or roughness in consistent lighting conditions |
| Skin tolerance self-assessment | Days 3, 7, and 14 of initial use | Not listed |
Objective before/after comparison to detect responder vs. non-responder status early; expression wrinkles are highly subject to lighting and facial position bias without photographic standardization
Contact dermatitis or irritant reaction identification; most reactions present within the first 2 weeks. Allows switching to every-other-day protocol or vehicle-only control if irritation occurs
Argireline Before and After
No visible changes expected. Argireline begins accumulating in the upper skin layers upon twice-daily application. Some users notice a mild smoothing or tightening sensation immediately after application due to the serum vehicle. Skin tolerance is established during this period.
Early wrinkle softening becomes apparent, especially on fine expression lines. The original Blanes-Mira study reported up to 30% wrinkle depth reduction by day 30. Surface roughness parameters begin to decrease measurably. Fine lines around the eyes and forehead show the most noticeable initial improvement.
Peak anti-wrinkle effects are typically reached in this window. The randomized Chinese clinical trial reported 48.9% total efficacy at 4 weeks with statistically significant roughness reduction (p < 0.01). Results vary based on concentration (10% formulations outperform lower concentrations), formulation quality, and individual skin penetration characteristics.
Maintenance of wrinkle reduction gains with continued twice-daily use. Deeper expression lines may show further gradual improvement. Best results are achieved with consistent high-concentration (10%) application combined with complementary peptides such as SNAP-8 or Matrixyl.
Effects are not permanent. Wrinkle depth gradually returns to baseline over 4-8 weeks after discontinuation as normal SNARE complex assembly and muscle contraction patterns resume. Restarting the protocol restores benefits. No rebound worsening has been reported.
What to Expect
Week 1: Don't expect visible changes yet. The peptide accumulates in the upper skin layers with twice-daily application. Some users notice a mild smoothing sensation immediately after applying the serum, but that's the hyaluronic acid vehicle, not the Argireline. This first week is about establishing skin tolerance.
Weeks 2 through 4: Fine expression lines start looking softer, particularly around the eyes and forehead. Blanes-Mira's original study [3] measured up to 30% wrinkle depth reduction by day 30 in responders. Surface roughness parameters begin to improve. Non-responders still see nothing at this point, and that's a real possibility.
Weeks 4 through 8: This is the peak effect window. Wang and colleagues [2] reported 48.9% composite efficacy at four weeks with p < 0.01 across roughness parameters. But the 2023 split-face study (PMC10665711) with 19 subjects found no statistically significant difference between treated and control sides. If you're a responder, deeper expression lines show clear softening. If you're not, eight weeks is a reasonable cutoff before concluding this peptide doesn't work for your skin. Some users report periorbital heaviness around this stage.
Weeks 8 through 12: Gains from the first two months hold steady with continued application. No long-term RCT data exists past four weeks, so this is extrapolation from mechanism. Many community users shift to once-daily maintenance or start incorporating breaks for subjective reassessment.
After stopping: Effects are not permanent. Normal SNARE complex assembly and muscle contraction patterns resume within four to eight weeks of discontinuation. Lines reappear gradually. No rebound worsening has been reported. Restarting the protocol restores whatever benefit you had before.
Detailed Timeline: Science vs Community
Peptide accumulates in stratum corneum (0.22% retention in in vitro models). No measurable change in wrinkle depth on imaging.
Some users report a mild immediate smoothing or "tightening" sensation: attributable to the serum vehicle (hyaluronic acid base), not the peptide. No visible wrinkle improvement.
Blanes-Mira 2002: up to 30% wrinkle depth reduction measurable by day 30 in responders. Surface roughness parameters begin to decrease.
Enthusiastic responders notice forehead lines and crow's feet looking softer, especially in low-light or morning face conditions. Non-responders see nothing.
Wang 2013: 48.9% composite anti-wrinkle efficacy at 4 weeks in responders (p<0.01). PMC10665711 (2023 RCT): no statistically significant change in n=19 double-blind study. Peak divergence between responder and non-responder groups.
Responders: noticeably smoother expression lines, especially dynamic wrinkles. Non-responders: no visible change by week 6–8: this is the typical cut-off for declaring non-response. Some users anecdotally describe periorbital heaviness at this stage.
No long-term RCT data beyond 4 weeks. Extrapolation from mechanism: continued twice-daily application maintains SNARE inhibition and sustains wrinkle reduction in responders.
Continued improvement plateaus; many users switch to maintenance dosing (once daily) or incorporate periodic breaks for subjective re-assessment.
Reversible mechanism: normal SNARE complex assembly and muscle contraction resume. Wrinkle depth returns to pre-treatment baseline over 4–8 weeks.
Consistent with science: lines reappear over 1–2 months. No rebound worsening reported. Users can resume protocol after break without loss of efficacy.
Pharmacokinetics
Source: No systemic pharmacokinetic data available. Argireline is a topical cosmeceutical peptide with negligible transdermal absorption. In vitro skin penetration studies (Kraeling et al. 2015, PMID 24754410) show only 0.22% of applied peptide is retained in the human stratum corneum, ~0.01% reaches the epidermis, and no detectable amounts reach the dermis or systemic circulation. No metabolites (deacetylated H2N-EEMQRR-NH2) were found in any skin layer, indicating the peptide remains intact but does not achieve meaningful systemic exposure.
Molecular Profile
Is Argireline Legal?
Argireline (Acetyl Hexapeptide-8) is classified as a cosmeceutical ingredient. It has no FDA approval for any medical indication and is not regulated as a drug. In the United States, products containing Argireline fall under cosmetics law (FDA 21 CFR) and do not require a prescription. The European Union regulates it under the EU Cosmetics Regulation with no restrictions on concentration.
The Cosmetic Ingredient Review Expert Panel has assessed Acetyl Hexapeptide-8 and confirmed its safety in cosmetic formulations. The EWG Skin Deep database rates the ingredient as low risk across all toxicity categories.
Argireline is not a WADA-prohibited substance and carries no restrictions for competitive athletes.
No pending regulatory changes affect Argireline's availability. It is sold in over-the-counter serums and as a raw cosmetic ingredient for DIY formulators.
This content is for informational purposes only and does not constitute medical advice. Consult a dermatologist or healthcare provider before starting any new skincare protocol.
Evidence grade: Phase 3 trial (Peptide Evidence Gap, October 2026)
Who Should Consider Argireline
- Adults over 30 with early expression lines seeking non-invasive wrinkle treatment
- Individuals who prefer topical anti-aging products over botulinum toxin injections
- People with dynamic wrinkles on forehead, crow's feet, or glabella
- Skincare enthusiasts building multi-peptide anti-aging protocols
- Those seeking to extend the interval between Botox appointments with supplemental topical care
- Individuals with needle aversion who want evidence-based anti-wrinkle cosmeceuticals
Related Peptides
What Changed for Argireline
Peptide Schedule Research TeamReviewed Apr 7, 202611 Citations
References
- [1]In Vitro Skin Penetration of Acetyl Hexapeptide-8 from a Cosmetic Formulation (Cutan Ocul Toxicol 2015) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [2]The Anti-Wrinkle Efficacy of Argireline in Chinese Subjects: A Randomized Placebo-Controlled Study (Am J Clin Dermatol 2013) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [3]A Synthetic Hexapeptide (Argireline) with Antiwrinkle Activity (Int J Cosmet Sci 2002) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [4]Pilot Study of Topical Acetyl Hexapeptide-8 in Treatment of Blepharospasm (J Neuroophthalmol 2013) (opens in a new tab)PubMed (opens in a new tab)PubMed
Additional References
- Acetyl Hexapeptide-8 in Cosmeceuticals: A Review of Skin Permeability and Efficacy (Int J Mol Sci 2025) (opens in a new tab)PubMed 40565185Review
- SNARE Modulators and SNARE Mimetic Peptides (Biomolecules 2022) (opens in a new tab)Review
- Investigating the Effects of Argireline with Hyaluronic Acids on Skin Wrinkles Using Visia Analysis (J Cosmet Dermatol 2023) (opens in a new tab)PubMed
- Acetyl Hexapeptide-8 as a Topical Alternative to Botulinum Toxin: A Review (J Drugs Dermatol 2025) (opens in a new tab)PubMed 40196949Review
- Small Peptides Patterned After SNAP-25 N-Terminus Inhibit SNARE Complex Assembly (J Neurochem 2004) (opens in a new tab)PubMed 14675156PubMed
- Cosmeceutical Peptides in the Framework of Sustainable Wellness Economy (Molecules 2020) (opens in a new tab)PubMed 33195061Review
- Oct 2022 (PMC10915729) (opens in a new tab)PubMed
Related Tools
Storage & Stability
Frequently Asked Questions
How popular is Argireline?
Hot. A popularity tier (hot, popular, emerging or niche), based on search volume and community activity.
Reddit: Very high: r/Skincar. Community mentions on Reddit: Very high: r/SkincareAddiction perennial topic. Open r/SkincareAddiction (opens in a new tab).
8 papers on PubMed, the US library of medical research. Search them on PubMed (opens in a new tab).
High search interest. A band for how often people search Google for the name each month.
These come from this site's peptide records. They are not live counts.